Cargando…
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous hematologic malignancy. In approximately 90% of cases the TP53 gene is in its wildtype state at diagnosis of this malignancy. As mouse double-minute-2 homolog (MDM2) is a primary repressor of p53, targeting this protein is an attractiv...
Autores principales: | Ciardullo, Carmela, Aptullahoglu, Erhan, Woodhouse, Laura, Lin, Wei-Yu, Wallis, Jonathan P, Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959162/ https://www.ncbi.nlm.nih.gov/pubmed/31004033 http://dx.doi.org/10.3324/haematol.2018.206631 |
Ejemplares similares
-
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
por: Aptullahoglu, Erhan, et al.
Publicado: (2023) -
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia
por: Aptullahoglu, Erhan, et al.
Publicado: (2023) -
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018) -
Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia
por: Barrow, Timothy M., et al.
Publicado: (2020) -
p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)